Belgian guidelines concerning central neural blockade in patients with drug-induced alteration of coagulation: an update.
Vandermeulen
E
E
Dept. of Anaesthesia, U.Z. Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Singelyn
F
F
Vercauteren
M
M
Brichant
J F
JF
Ickx
B E
BE
Gautier
P
P
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001530:Belgium; D005170:Factor X / Q000037:antagonists & inhibitors; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006406:Hematoma / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009407:Nerve Block; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K; D005170:Factor X; D013917:Thrombin